In this study, we found that many patients with BTC had a high mutation frequency of oncogenes such as KRAS (i.e., p.G12S, p.G12R, p.G12D, and p.G13D) and TP53 (i.e., p. R282W, p.P222Sfs*26, p.R283_E285delinsHTK, and c.560-1G>C) in both bile and tumor tissues. The gene discussed is KRAS; the disease is neoplasm.